IL17A and neoplasm: The B16F0 melanoma cells with BMSCs, which were pretreated with IL-17 and IFNγ jointly, gave more aggressive tumor growth compared to control B16F0 melanoma cells (5.2-fold increase in tumor weight, and 4-fold increase in tumor size).